Neuropsychiatric Program


Significant overlap exists among neuropsychiatric diseases including anxiety, sleep disorders, and post-traumatic stress disorder, all of which may be aided by cannabinoid therapeutics.

Anxiety and sleep disorders affect over 20% of adults in the U.S. (1) , and are strongly correlated which each other as well as with depression. Chronic anxiety and sleep disorders are thought to contribute to a number of other health conditions, including cardiac disease and pain (2) , and also lead to significant loss of productivity and quality of life for sufferers. PTSD, though impacting a smaller portion of the population, still affects about 8 million men, women and children in the U.S. each year, and lacks effective treatments (3). 

Cannabinoids have shown promising anti-anxiety effects and are thought to cause this through action on both serotonin and endocannabinoid pathways (4,5). They have also been found to improve sleep quality and reduce sleep disturbances in patients with organic sleep disorders (6), and these effects have promise in treating PTSD as well (7, 8).


1. Anxiety and Depression Association of America. 

2. Li et al., Int J Cardiol 2014

3. U.S. Dept of Veteran's Affairs

4. Lee et al. British J Pharmacy 2017. 

5. Patel et al. Neurosci and Biobehav Review 2017. 

6. Chagas et al. J Clin Pharma and Therapeutics 2014. 

7. Berardi et al. Pharmacological Research 2016. 

8. Zer-Aviv et al. Behavioural Pharmacology 2016

neuro chart.png